SecBot SecBot
Biotech Drug Report Generated Aug 20, 2026

Zircaix

TLX·Telix Pharmaceuticals Limited
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3 (ZIRCON) completed; BLA under FDA review
Time to market
BLA for ccRCC under FDA review per Telix's May 2026 release; US commercialization would follow an FDA decision whose date is not confirmed in available data (potentially within ~12 months of approval).
Why 4/10
No hard, dated binary in the next ~12 months in available data: Zircaix's ccRCC BLA was described as "pending" as of the May 2026 ZIRCON release, and no PDUFA date or approval is recorded in SecBot's FDA/catalyst data, the nearest company-level event is the September 22, 2026 R&D Day, which is not a regulatory decision, so this mid-/late-stage asset at a diversified commercial-stage company scores 4.
Actionable Insight NEUTRAL

Watch for (1) an FDA action/PDUFA announcement on the Zircaix BLA in ccRCC, the single biggest binary for this drug, undated in available data, and (2) the September 22, 2026 R&D Day, where Telix may update Zircaix launch/regulatory timing.

Price Chart

Loading chart...

Executive Summary

Zircaix (TLX250-Px / TLX250-CDx, zirconium-89 girentuximab) is Telix Pharmaceuticals' Phase 3-completed PET imaging agent for clear cell renal cell carcinoma, with a US BLA that Telix described as pending as of its May 2026 ZIRCON data publication. SecBot internal data (company press releases, SEC filings, FDA/catalyst tables) is the sole grounding, with real GlobeNewswire and EDGAR URLs cited.

How It Works

A PET imaging "tracer" for kidney cancer: a radioactive form of zirconium (Zr-89) is attached to an antibody (girentuximab) that binds to CAIX, a protein heavily present on clear cell renal cell carcinoma cells. Injected into a patient, it lights up suspicious kidney masses on a PET/CT scan so doctors can better tell malignant from benign lesions, the diagnostic "see" companion to Telix's therapy pipeline, which uses the same targeting antibody.

Trial Status

The pivotal Phase 3 ZIRCON trial is complete. In May 2026 Telix published an independent analysis of ZIRCON data in European Urology showing Zircaix PET/CT is highly predictive of renal malignancy across subtypes (98% positive predictive value cited); Telix noted that analysis is exploratory and separate from the pending BLA for ccRCC. No approval, CRL, or PDUFA date for Zircaix appears in SecBot's FDA/catalyst records through mid-August 2026.

The Two-Sided Case

▲ Bull Case5
Phase 3 ZIRCON data (published May 2026 in European Urology) show Zircaix PET/CT highly predictive of renal malignancy across all subtypes, not just ccRCC, with a 98% positive predictive value, a strong efficacy narrative if the FDA follows. (GlobeNewswire Zircaix release)
Commercial platform is firing: H1 2026 revenue of $477M (+22% YoY) and net profit of $38M vs a $2M loss a year earlier, with FY26 revenue guidance at the upper end of $950M-$970M and total revenue/other income guided above $1B. (Telix H1 2026 results release)
Same-target franchise synergies: the therapeutic sibling TLX250-Tx (177Lu-girentuximab) just entered Phase 3 LUTEON for ccRCC, extending the CAIX platform beyond imaging. (LUTEON release)
Wall Street support: price-target consensus mean of $21.29 (4 analysts) vs a $12.12 stock price (~76.5% implied upside), with Citi, HC Wainwright and Wedbush all Buy/Outperform as of July 2026.
Institutional accumulation in 2026-Q2 13Fs: UBS roughly doubled (+317% shares), BlackRock doubled, Morgan Stanley +42.5% and JPMorgan +35.2%.
▼ Bear Case4
Imaging agents are typically lower-revenue, reimbursement-sensitive products; Telix's own GOZELLIX FDA approval (March 2025) moved TLX only ~+1.1% in one day / +4.3% in five, suggesting approval alone may not be a huge share-price catalyst.
The exploratory multi-subtype analysis is NOT part of the pending BLA, so the near-term label is narrower (ccRCC) and label-expansion is a later event. (Telix press summary)
Dilution overhang: H1 2026 results disclosed an ATM facility for potential equity issuance, alongside a $600M convertible bond refinancing and raised R&D guidance of $230-270M. (H1/Q2 2026 press summaries)
SecBot's 90-day local bull/bear heuristic is net bearish (13F trims at Millennium and UBS in earlier quarters; one window with ~41% weighted short-volume flow), although actual short interest is tiny at ~0.08% of estimated shares outstanding, no squeeze dynamics.

Upcoming Catalysts

  • FDA action/PDUFA announcement on the Zircaix (TLX250-CDx) BLA in clear cell renal cell carcinoma, undated in available data
  • Telix R&D Day in New York City on September 22, 2026, possible Zircaix regulatory/launch timing updates
  • H2 2026 quarterly updates (next earnings) for any BLA status or commercial-launch commentary
  • Potential European or ex-US regulatory filings/decisions for TLX250-CDx (not confirmed in local data)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Telix Pharmaceuticals Limited PRESS-RELEASE TLX ·Originating report

Sources · 8

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 globenewswire.com5 globenewswire.com6 globenewswire.com7 sec.gov8 sec.gov